Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BiomX ( (PHGE) ) has issued an announcement.
On October 16, 2025, BiomX Inc. held its Annual Meeting of Stockholders, where all proposed business items were approved. Stockholders elected three Class II directors to the board, authorized a potential reverse stock split, and ratified the selection of Kesselman & Kesselman as the independent public accounting firm for fiscal 2025. These decisions could impact the company’s governance and financial structure, potentially influencing its market positioning and operational strategies.
The most recent analyst rating on (PHGE) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. operates in the biotechnology industry, focusing on developing innovative microbiome-based therapeutics. The company targets various health conditions by leveraging phage therapy and other microbiome technologies.
Average Trading Volume: 4,149,790
Technical Sentiment Signal: Sell
Current Market Cap: $15.69M
See more insights into PHGE stock on TipRanks’ Stock Analysis page.